NCT07770672
- Conditions
- Digestive System Diseases, Digestive System Neoplasms, ESCC, +8 more
- Locations
-
- Zhongshan Hospital, Fudan University Shanghai, China
Clinical trial condition
ESCC
Explore clinical trials studying ESCC. Study availability and eligibility vary by location and protocol.
21 public trials
10 recruiting studies
ESCC trial results
NCT07701681
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +17 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
Not yet recruiting
Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)
NCT07584031
- Conditions
- ESCC
- Locations
-
Not specified
Not yet recruiting
Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT07533305
- Conditions
- ESCC, First-line Therapy, QL1706
- Locations
-
Not specified
Not yet recruiting
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
NCT07531979
- Conditions
- Becotatug Vedotin, Chemotherapy, EGFR ADC, +3 more
- Locations
-
- Tianjin Medical University Cancer Institute and Hospital Tianjin, China
Not yet recruiting
SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
NCT07524374
- Conditions
- ESCC
- Locations
-
- Shanghai Chest Hospital Shanghai, China
NCT07493993
- Conditions
- ESCC
- Locations
-
- Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin Municipality, China
Not yet recruiting
Adebrelimab Neoadjuvant Treatment for Resectable ESCC
NCT07388095
- Conditions
- ESCC
- Locations
-
Not specified
Not yet recruiting
TAS-102 Plus Radiotherapy in Elderly ESCC
NCT07196345
- Conditions
- ESCC, Radiotherapy, TAS 102
- Locations
-
- The First Affiliated Hospital of Shandong First Medical University Jinan, Shandong, China
Not yet recruiting
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
NCT06531291
- Conditions
- Biliary Tract Cancer, Biliary Tract Diseases, Biliary Tract Neoplasms, +15 more
- Locations
-
- Renji hospital Shanghai, Shanghai Municipality, China